More importantly, multifunctional nanocomposites can simultaneously carry multiple therapeutic agents, facilitating combination therapy, and can be integrated with imaging probes for real-time monitoring, providing further options for personalized treatment (89).So far, the FDA has approved three nanomedicines for the treatment of CRC: Onivyde (irinotecan liposome injection), Injectafter Ferinject (Iron carboxymaltose colloid), and Doxil synergized with mAbs (Liposomal doxorubicin, anti-PD-1 and CTLA-4 mAbs). Here, CTLA4 is linked to colorectal carcinoma.